Amarin Corporation PLCChange company Symbol lookupSelect an option...AMRN Amarin Corporation PLCNEOV NeoVolta IncFIISO Financial Institutions IncKA Kineta IncTCS Container Store Group IncMLGO MicroAlgo IncINDI indie Semiconductor IncJCI Johnson Controls International PLCFPAY FlexShopper IncCMSA CMS Energy CorpGo
Based in Ireland
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
American Depositary Receipt (ADR) Fee
ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees
|
|
|
|
| |
AMRN's position in the Biotechnology industry
| Industry Peers | LLY | |
|---|---|---|
Summary | ||
| Company Profile | Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The... | Eli Lilly and Company is engaged in drug manufacturing businesses. It discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products... Go to LLY summary |
| 52-Week Change | VS. INDUSTRY | 77.10% |
| Market Cap | VS. INDUSTRY | $522.6B |
| Beta | VS. INDUSTRY | 0.3 |
| Dividend Yield | VS. INDUSTRY | 0.82% |
| P/E (TTM, GAAP) | VS. INDUSTRY | 76.49x |
| Data as of | ||
Fundamentals | ||
| Total Revenue (TTM) | VS. INDUSTRY | $29.5B |
| Profit Margin | VS. INDUSTRY | 22.01% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | 10.08% |
| Revenue Growth (TTM) | VS. INDUSTRY | 1.53% |
| Data as of |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.